• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Bayer acquires rights to Cytokinetics` heart drug in Japan

    REUTERS

    Cytokinetics Presents Aficamten Data in Hypertrophic Cardiomyopathy

    GLOBENEWSWIRE

    Cytokinetics Presents GALACTIC-HF Data at AHA 2024

    GLOBENEWSWIRE

    Cytokinetics Announces Initiation of Ph 1 Clinical of CK-4015089

    GLOBENEWSWIRE

    Cytokinetics Reports Q3 2024 Financial Results

    GLOBENEWSWIRE

    Cytokinetics Announces Six Presentations at AHA Scientific Sessions

    GLOBENEWSWIRE

    Cytokinetics Reports Inducement Grants Under Nasdaq LR5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Announce Third Quarter Results on November 6, 2024

    GLOBENEWSWIRE

    Cytokinetics Highlights Cardiac Myosin Modulation Progress

    GLOBENEWSWIRE

    Cytokinetics Announces Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Host Investor & Analyst Day on October 16, 2024

    GLOBENEWSWIRE

    Cytokinetics Presents SEQUOIA-HCM Data At HFSA Annual Meeting

    GLOBENEWSWIRE

    Cytokinetics Presents Additional Data From SEQUOIA-HCM Study

    GLOBENEWSWIRE

    Cytokinetics Calls for Proposals for Seventh Annual Grant Program

    GLOBENEWSWIRE

    Cytokinetics Announces Upcoming Presentations At Meetings

    GLOBENEWSWIRE

    Cytokinetics Announces Data From Phase 1 Study of CK-4021586

    GLOBENEWSWIRE

    Cytokinetics Announces 2 Presentations At Pharmacology Meeting

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing

    GLOBENEWSWIRE

    Cytokinetics Shares Additional SEQUOIA-HCM Data At EU Society Of Cardiology 2024

    GLOBENEWSWIRE

    Cytokinetics Presents New Aficamten Safety Data At EU Society Of Cardiology 2024

    GLOBENEWSWIRE

    Cytokinetics to Participate in September Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Reports Second Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    GLOBENEWSWIRE

    Intellia Gets Authorization For NTLA-3001 Phase 1/2 Trial In AATD

    GLOBENEWSWIRE

    Cytokinetics to Announce Second Quarter Results on August 8, 2024

    GLOBENEWSWIRE

    Cytokinetics To Present Seven Studies At ESC Congress 2024

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Initiates Phase 1 Study Of Aficamten In Healthy Japanese

    GLOBENEWSWIRE

    Cytokinetics confirms acquisition talks with Novartis were halted

    INVESTING

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Participate in June Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Announces Closing of Public Offering of Common Stock

    GLOBENEWSWIRE

    Cytokinetics secures up to $575M in royalty deal, frustrating investors

    BIOPHARMADIVE

    Cytokinetics Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    Cytokinetics Announces Pricing of Public Offering of Common Stock

    GLOBENEWSWIRE

    Cytokinetics Hosts Muscle Biology Research Symposium

    GLOBENEWSWIRE

    Cytokinetics Announces Five Aficamten Presentations At ESC Congress 2024

    GLOBENEWSWIRE

    Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy

    CLINICALTRIALSARENA

    Cytokinetics Announces SEQUOIA-HCM Primary Results At ESC, Published In NEJM

    GLOBENEWSWIRE

    Cytokinetics shows hand in high stakes rivalry with BMS` Camzyos

    FIERCE BIOTECH

    Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors

    STAT NEWS

    Cytokinetics Pediatric HCM Trial CEDAR-HCM Starts

    GLOBENEWSWIRE

    Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

    GLOBENEWSWIRE

    Cytokinetics Reports First Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Cytokinetics to Hold Annual Meeting of Stockholder

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics SEQUOIA-HCM Primary Results Event at ESC-HF 2024

    GLOBENEWSWIRE

    Cytokinetics to Announce First Quarter Results on May 8, 2024

    GLOBENEWSWIRE

    Cytokinetics Announces Late-Breaking Trial Presentations at ESC Congress

    GLOBENEWSWIRE

    Cytokinetics Presents Additional 48-Week Data From FOREST-HCM

    PRESS RELAESE

    Cytokinetics Presents Additional 48-Week Data From FOREST-HCM at ACC

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Participate in the 23rd Annual Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Announces Four Upcoming Presentations at American C of Cardiology

    GLOBENEWSWIRE

    Cytokinetics to Participate in March Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

    GLOBENEWSWIRE

    Cytokinetics not in sale process, CEO says

    FIERCE BIOTECH

    Cytokinetics Reports Fourth Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.